Why Eli Lilly is outpacing Novo Nordisk in the GLP-1 race
Lilly's blockbuster quarter and raised guidance contrast sharply with Novo's stumble on lower pricing
Eli Lilly has cemented its lead over Novo Nordisk in the GLP-1 market, a shift that reflects not just product strength but diverging commercial strategies in a space both companies spent billions to dominate.
The gap widened sharply this quarter. Eli Lilly raised its 2026 revenue guidance to $85 billion to $87 billion, up from a prior forecast of $82 billion to $85 billion, driven by surging sales of Zepbound and Mounjaro. Novo Nordisk, by contrast, saw its shares fall 5% after disappointing guidance, according to CNBC and Morningstar reports.
Novo's stumble centered on Wegovy, its oral GLP-1 pill. The company's CEO defended the drug's economics even as lower prices weighed on sales, signaling a bet that volume growth could offset margin compression. But Wall Street has grown skeptical of that calculus. Investors remain unconvinced Novo Nordisk has a clear path back to sustainable growth as Eli Lilly's competition intensifies, marking a stark reversal from the era when Novo's early dominance in injectable GLP-1s seemed unshakeable.
The divergence poses a strategic question neither company can dodge: whether the GLP-1 market rewards pricing discipline or rapid market share gains through discounting. Eli Lilly's raise suggests its portfolio can sustain both growth and pricing power. Novo's decline signals the market doubts its lower-price strategy delivers the same payoff. For investors and patients, the outcome will shape how these drugs reach market in years ahead.
